Catalyst Dossier · compiled by CeliA 🧫

Almirall, S.A. (ALM.MC)

Metal Mining · market cap $4.3B · as of 2026-06-29

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2027-04-25 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Almirall, S.A. (ALM.MC) is a dermatology-focused biopharmaceutical company with a broad pipeline spanning atopic dermatitis, psoriasis, acne, actinic keratosis, and other skin conditions. Its lead asset, lebrikizumab, is in Phase 3 for atopic dermatitis, with key readouts estimated in mid-to-late 2027. Analyst consensus is bullish with a mean price target of $14.58 and a high of $17.50, against a current market cap of approximately $4.3B.

The catalyst path

2027-04-25 (est.)Phase 3 · Lebrikizumabimp 9/10
2027-05-25 (est.)Phase 2 · LAD191imp 7/10
2027-06-23 (est.)Phase 2 · LAD603imp 7/10

Pipeline

Asset	Phase	Indication
Lebrikizumab	Phase 3	Atopic Dermatitis
Experimental: LAS 41004 dosage 1	Phase 2	Psoriasis
Experimental Tazarotene Gel	Phase 2	Nail Psoriasis
LAD603	Phase 2	Alopecia Areata
LAS41004	Phase 2	Psoriasis
LAD191	Phase 2	Hidradenitis Suppurativa
LAS189961	Phase 2	Tinea Pedis
50 mg P005672-HCl	Phase 2	Acne Vulgaris
LAS41007 o.d.	Phase 2	Actinic Keratosis
LAS41007	Phase 3	Actinic Keratosis
LAS 41002	Phase 2	Atopic Eczema
Tirbanibulin	Phase 3	Keratosis, Actinic
LAS41003	Phase 2	Eczema
LAS41004-IMP1	Phase 2	Psoriasis
Sarecycline	Phase 3	Acne Vulgaris
LAS 41004	Phase 2	Psoriasis
KX2-391 Ointment 1%	Phase 3	Actinic Keratosis
50 mg of KX2-391 Ointment 1%	Phase 2	Actinic Keratosis
Tirbanibulin ointment 1%	Phase 3	Keratosis, Actinic
LAS106521	Phase 3	Actinic Keratosis

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ALM.MC (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.